Suloctidil [1-(4-isopropyl-thiophenyl)-2-n-octylaminopropanol, Continental Pharma, Belgium] is a drug which inhibits platelet aggregation in human beings and possesses antiplatelet aggregation and antithrombotic properties in several animal models. In the present study, the acute effect of suloctidil on vascular prostacyclin activity was evaluated in rats.. Male CD rats (250-300 g) were given the drug (200-400 mg/kg b.w.) orally 1 h before testing. Prostacyclin activity was measured as the plotelet aggregation inhibitory potency of supernatant buffer following 4 min incubation with rings of either abdominal aorta or inferior vena cava. Treatment with suloctidil did not induce any significant modification of prostacyclin activity. In contrast, in vivo platelet aggregation induced by i.v. infusion of ADP (1 mg/kg) or collagen (2.6 mg/kg) was significantly (p < 0.001) inhibited. It is su.ggested that suloctidil may interfere with platelet function without affecting the potential antithrombotic activity of the vascular wall.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.